- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elbit mulls disposition of GE windfall
Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed
Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed Ultrasound subsidiary for $228 million in April (SCAN 4/29/98). Elbit executives say their company is defining its strategic direction in healthcare and is investigating various technologies and activities that would complement its medical imaging operations.
Elbit recorded a one-time net profit for its first quarter of $91.2 million on the sale, and returned some of the money to its shareholders in the form of a $1 a share one-time dividend that was paid on June 30. There are about 21.5 million shares of Elbit stock outstanding, leaving Elbit with a substantial sum of money to put to use.
Elbit also released financial results for its second quarter (end-June) indicating that the company posted revenues of $83.1 million, up 5% compared with $79.2 million in the same period the year before. Elbit's Elscint subsidiary contributed $81.7 million in sales in the most recent quarter, with the rest coming from the company's Elbit Medical Services imaging services business. Elscint had revenues of $77.1 million in the second quarter of 1997. Elbit recorded net income of $3.1 million for the period, compared with $2.5 million in the second quarter of 1997.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
